Objective: To investigate the long-term prophylactic effect of a vaccine on lower urinary tract infections (UTI) of bacterial and the impact of the intensity of the symptoms on the quality of life (QoL). Methods: Adult female could be enrolled in this study if they had acute UTI at the enrolment visit and bacterial microbiological count of ≥103 CFU/mL of Escherichia coli. Results: A total of 21 patients were included. Fifteen days after the administration of a vaccine for 3 months, the number of infections dropped almost to zero. Significant differences were observed in the QoL score (p < 0.05). The safety profile was good. Conclusions: In patients diagnosed with recurrent UTI and treated for 3 months with the vaccine the number of UTI episodes fell very quickly (15 days), and patients remained free of episodes and improved their QoL significantly for 1 year. These results suggest that bacterial vaccines are a possible effective alternative in the prevention of recurrent UTI.

Keywords:
Urinary tract infections, Genitourinary infections, Inmunotherapy, Bacterial extract
1.
García-larrosa A, Alexe O. Efficacy and Safety of a Medical Device versus Placebo in the Early Treatment of Patients with Symptoms of Urinary Tract Infection : A Randomized Controlled Trial.
Clin Microbiol
. 2016; 5(01): 1–5.
2.
Hooton TM, Scholes D, Stapleton AE, Roberts PL, Winter C, Gupta K, et al. A prospective study of asymptomatic bacteriuria in sexually active young women.
N Engl J Med
. 2000 Oct; 343(14): 992–7.
3.
Jiménez Cruz JF, Broseta E, Gobernado M. [Urinary infection].
Actas Urol Esp
. 2002 Sep; 26(8): 563–73.
4.
Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs.
Am J Med
. 2002 Jul; 113(113 Suppl 1A): 5S–13S.
5.
Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy.
Eur Urol
. 2008 Nov; 54(5): 1164–75.
6.
Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women.
JAMA
. 1999 Feb; 281(8): 736–8.
7.
Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections.
Ann Intern Med
. 2001 Jul; 135(1): 41–50.
8.
Beerepoot M, Geerlings S. Non-Antibiotic Prophylaxis for Urinary Tract Infections.
Pathogens
. 2016 Apr; 5(2):E36.
9.
Lüthje P, Brauner A. Novel Strategies in the Prevention and Treatment of Urinary Tract Infections.
Pathogens
. 2016 Jan; 5(1):E13.
10.
de Servi B, Ranzini F, Piqué N. Effect of Utipro(®) (containing gelatin-xyloglucan) against Escherichia coli invasion of intestinal epithelial cells: results of an in vitro study.
Future Microbiol
. 2016 May; 11(5): 651–8.
11.
Kücüksezer UC, Palomares O, Rückert B, Jartti T, Puhakka T, Nandy A, et al. Triggering of specific Toll-like receptors and proinflammatory cytokines breaks allergen-specific T-cell tolerance in human tonsils and peripheral blood.
J Allergy Clin Immunol
. 2013 Mar; 131(3): 875–85.
12.
Kang SS, Yang JS, Kim KW, Yun CH, Holmgren J, Czerkinsky C, et al. Anti-bacterial and anti-toxic immunity induced by a killed whole-cell-cholera toxin B subunit cholera vaccine is essential for protection against lethal bacterial infection in mouse pulmonary cholera model.
Mucosal Immunol
. 2013 Jul; 6(4): 826–37.
13.
Nau GJ, Richmond JF, Schlesinger A, Jennings EG, Lander ES, Young RA. Human macrophage activation programs induced by bacterial pathogens.
Proc Natl Acad Sci USA
. 2002 Feb; 99(3): 1503–8.
14.
Salles MF, Mandine E, Zalisz R, Guenounou M, Smets P. Protective effects of murine monoclonal antibodies in experimental septicemia: E. coli antibodies protect against different serotypes of E. coli.
J Infect Dis
. 1989 Apr; 159(4): 641–7.
15.
O’Hanley P, Lalonde G, Ji G. Alpha-hemolysin contributes to the pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney: efficacy of an alpha-hemolysin vaccine in preventing renal injury in the BALB/c mouse model of pyelonephritis.
Infect Immun
. 1991 Mar; 59(3): 1153–61.
16.
Russo TA, McFadden CD, Carlino-MacDonald UB, Beanan JM, Olson R, Wilding GE. The Siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate.
Infect Immun
. 2003 Dec; 71(12): 7164–9.
17.
Pecha B, Low D, O’Hanley P. Gal-Gal pili vaccines prevent pyelonephritis by piliated Escherichia coli in a murine model. Single-component Gal-Gal pili vaccines prevent pyelonephritis by homologous and heterologous piliated E. coli strains.
J Clin Invest
. 1989 Jun; 83(6): 2102–8.
18.
Langermann S, Palaszynski S, Barnhart M. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination.
Science
. 1997 Apr 25; 276(5312): 607–11.
19.
Langermann S, Möllby R, Burlein JE, Palaszynski SR, Auguste CG, DeFusco A, et al. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli.
J Infect Dis
. 2000 Feb; 181(2): 774–8.
20.
Bauer HW, Alloussi S, Egger G, Blümlein HM, Cozma G, Schulman CC; Multicenter UTI Study Group. A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections.
Eur Urol
. 2005 Apr; 47(4): 542–8.
21.
de la Fe C, Assuncão P, Ramírez AS, Poveda JB. Inactivation of Mycoplasma species involved in contagious agalactia.
Berl Munch Tierarztl Wochenschr
. 2004 Jan-Feb; 117(1-2): 1–5.
22.
Jeannin P, Magistrelli G, Goetsch L, Haeuw JF, Thieblemont N, Bonnefoy JY, et al. Outer membrane protein A (OmpA): a new pathogen-associated molecular pattern that interacts with antigen presenting cells-impact on vaccine strategies.
Vaccine
. 2002 Dec; 20 Suppl 4:A23–7.
23.
Jeannin P, Magistrelli G, Herbault N, Goetsch L, Godefroy S, Charbonnier P, et al. Outer membrane protein A renders dendritic cells and macrophages responsive to CCL21 and triggers dendritic cell migration to secondary lymphoid organs.
Eur J Immunol
. 2003 Feb; 33(2): 326–33.
24.
Grabe M, Bartoletti R, Bjerklund-Johansen H.
Guidelines on Urological Infections
. Eur Assoc Urol; 2015.
25.
Bonkat G, Pickard R, Bartoletti R. Guidelines on Urological Infections [Internet]. European Association of Urology; 2018. Available from: http://uroweb.org/guideline/urological-infections/.
26.
Bauer HW, Rahlfs VW, Lauener PA, Blessmann GS. Prevention of recurrent urinary tract infections with immuno-active E. coli fractions: a meta-analysis of five ­placebo-controlled double-blind studies.
Int J Antimicrob Agents
. 2002 Jun; 19(6): 451–6.
27.
Lorenzo-Gómez MF, Padilla-Fernández B, García-Criado FJ, Mirón-Canelo JA, Gil-Vicente A, Nieto-Huertos A, et al. Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics.
Int Urogynecol J Pelvic Floor Dysfunct
. 2013 Jan; 24(1): 127–34.
28.
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al.; WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.
Lancet Infect Dis
. 2018 Mar; 18(3): 318–27.
29.
Ernst EJ, Ernst ME, Hoehns JD, Bergus GR. Women’s quality of life is decreased by acute cystitis and antibiotic adverse effects associated with treatment.
Health Qual Life Outcomes
. 2005 Jul; 3(1): 45.
30.
Lorenzo-Gómez MF, Padilla-Fernández B, García-Cenador MB, Virseda-Rodríguez ÁJ, Martín-García I, Sánchez-Escudero A, et al. Comparison of sublingual therapeutic vaccine with antibiotics for the prophylaxis of recurrent urinary tract infections.
Front Cell Infect Microbiol
. 2015 Jun; 5(50): 50.
31.
Taha Neto KA, Nogueira Castilho L, Reis LO. Oral vaccine (OM-89) in the recurrent urinary tract infection prophylaxis: a realistic systematic review with meta-­analysis.
Actas Urol Esp
. 2016 May; 40(4): 203–8.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.